title: Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation.
abstract: Safety and efficacy of a biologically active derivative of vitamin B(5) (pantethine) on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) metabolism was studied in North American subjects at conventional low to moderate cardiovascular disease (CVD) risk. A total of 120 subjects initiated a therapeutic lifestyle change (TLC) diet 4 weeks before randomization (baseline) and maintained the diet throughout a 16-week study period; at baseline, subjects were randomized in a triple-blinded manner to either pantethine (600 mg/d, baseline to week 8, and 900 mg/d, weeks 9-16) or identically labeled, nonbiologically active placebo (n = 60 per group). We hypothesized that pantethine would lower TC and low-density lipoprotein in low-CVD-risk North American subjects in a similar manner as reported in high-CVD-risk subjects studied mainly in Italy and Japan. While sustaining a TLC diet and in comparison with placebo, pantethine demonstrated significant (P < .005) and sustained reductions (from baseline to week 16) in TC (6 mg/dL, 0.16 mmol/L, 3%), LDL-C (4 mg/dL, 0.10 mmol/L, 4%), and apolipoprotein B (4 mg/dL, 0.04 g/L, 5%). Our data suggest that pantethine supplementation for 16 weeks (600 mg/d for weeks 1-8 then 900 mg/d for weeks 9-16) is safe and significantly lowers TC and LDL-C over and above the effect of TLC diet alone. Although the absolute magnitude of these effects was small in these low- to moderate-risk North Americans (4-6 mg/dL), the results are noteworthy as prior studies have shown that, for each 1 mg/dL (0.026 mmol/L) reduction in LDL-C, there is a concomitant 1% reduction in overall future CVD risk.
authors.affiliation: The Princeton Longevity Center, Princeton, NJ 08540, USA. jrumberger@theplc.net
authors.forename: John A
authors.initials: JA
authors.lastname: Rumberger
authors.forename: Joseph
authors.initials: J
authors.lastname: Napolitano
authors.forename: Isao
authors.initials: I
authors.lastname: Azumano
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Kamiya
authors.forename: Malkanthi
authors.initials: M
authors.lastname: Evans
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006293:Health Promotion; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009656:North America; D010204:Pantetheine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D014803:Vitamin B Complex / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D014803:Vitamin B Complex; D010204:Pantetheine; C005425:pantethine; D002784:Cholesterol